Additionally, an inhibitor of enhancer of zeste homologue 2 (EZH2) can enhance sensitivity of SNF5‐deficient cells to cisplatin, a novel treatment strategy based on SNF5 expression involving EGFR‐targeted chemotherapy or cisplatin combined with EZH2 inhibitor is proposed for bladder cancer management [58]. This evidence concerns the gene SMARCB1 and urinary bladder cancer.